Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 3,675.88๏ฟฅ. Average daily volumn in 3 months 2.29M. Market cap 5.90T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 3,589.00๏ฟฅ. Total volume : 1.85M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
3,589.00๏ฟฅ
Change
13.00
Volume
1.85M

Previous Close3,576.00
Open3,565.00
Day Range3,540.00-3,597.00
Bid0.00 x N/A
Ask0.00 x N/A
Volume1.85M
Average Volume2.29M
Market Cap5.9T
Beta0.66
52 Week Range3,258.00-4,640.00
Trailing P/E15.24
Foward P/E18.87
Dividend (Yield %)2.30%
Ex-Dividend Date2022-06-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2021 were 999.76B an increase( +27.1%) over the years 2020 revenue that were of 786.95B. In 2021 the company's total earnings were 303B while total earnings in 2020 were 214.73B( +41.59%).


Loading ...



Organization

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept... , and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Market Cap:
5.90T
Revenue:
999.76B
Total Assets:
1.54T
Total Cash:
267.75B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Source from : ใƒ‹ใƒƒใ‚ฑใ‚คใƒปใ‚จใ‚คใ‚ธใ‚ข - 23 days ago

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...See details»


Chugai Pharmaceutical Co Ltd - Stock Valuation CHGCF

Source from : Morningstar%2c Inc. - 14 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Chugai introduces Vabysmo intravitreal injection to treat AMD associated with subfoveal choroidal neovascularization and DME

Source from : Pharmabiz - 1 month ago

Chugai Pharmaceutical Co., Ltd. announced that it launched anti VEGF/anti Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 mg/mL [generic name: faricimab (genetical recombination)] for the ...See details»


Japan to purchase antibody cocktail for Covid-19 treatment

Source from : Hindustan Times - 1 year ago

Chugai Pharmaceutical concluded the agreement with Roche in December for the production and marketing in Japan of the antibody cocktail for the virus treatment. A cocktail of two virus ...See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,...

Source from : Benzinga.com - 14 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


Spinal Muscular Atrophy Market To Surpass US$ 4,346.33 Million By 2030 - Coherent Market Insights'

Source from : Middle East North Africa Financial Network - 14 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


rare diseases

Source from : PMLiVE - 1 month ago

AstraZenecaโ€™s (AZ) rare disease group subsiduary Alexion has reached a settlement agreement with Chugai Pharmaceutical Co (Chugai). ... of people affected by rare diseases.โ€. As an international, ...See details»


Chugai Pharmaceutical Co. Ltd.

Source from : Wall Street Journal - 23 days ago

1 Day CHGCF -2.07% DJIA -0.13% S&P 500 0.22% Health Care/Life Sciences 0.47% Tatsuro Kosaka Chairman & Chief Executive Officer Chugai Pharmaceutical Co., Ltd., Asahi Group Holdings Ltd. Osamu ...See details»


Chugai Pharmaceutical Co Ltd - Stock Valuation CUP

Source from : Morningstar%2c Inc. - 13 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


Chugai introduces Vabysmo intravitreal injection to treat AMD associated with subfoveal choroidal neovascularization and DME

Source from : Pharmabiz - 1 month ago

Chugai Pharmaceutical Co., Ltd. announced that it launched anti VEGF/anti Ang-2 bispecific antibody Vabysmo Intravitreal Injection 120 mg/mL [generic name: faricimab (genetical recombination)] for the ...See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,346.33 Million by 2030 - Coherent Market Insights

Source from : WFMZ-TV - 14 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


CHUGAI PHARMACEUTICAL CO., LTD.

Source from : MSN - 18 days ago

Chairman of the Board of Directors, President, Chief Executive Officer, Representative Director Toshiaki Itagaki Chief Financial Officer, Senior Executive Officer, Manager of Finance Control Unit ...See details»


Spinal Muscular Atrophy Market to Surpass US$ 4,346.33 Million by 2030 - Coherent Market Insights

Source from : Finanznachrichten - 14 days ago

For instance, in June 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had obtained regulatory approval from the Ministry of Health, Labor and ...See details»


CHGCY Chugai Pharmaceutical Co., Ltd.

Source from : Seeking Alpha - 14 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»